Use the hyperlinks, where available to access additional clinical trial information.
Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Eli Lilly and Company
Other Non-Commercial Sponsor
St Jude Children's Research Hospital
Eligible patients will be separated into two experimental groups; Experimental Group A will receive prexasertib + cyclophosphamide and Experimental Group B: prexasertib + gemcitabine. Participants from each group will receive combination treatment given intravenously (IV) for up to a total of 24 months.